Renke Maas

16PUBLICATIONS
59CO-AUTHORS
Molecular targetsToxicology (incl. clinical toxicology)PharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)Characterisation of biological macromolecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jul 24, 2026
Treatment with dapagliflozin and empagliflozin reduces concentrations of N4-acetylcytidine in plasma, a biomarker associated with vascular damage.

|Jul 16, 2026
Development and analysis of a SmPC-based machine-readable dataset of contraindications for clinical decision support and real-world data analysis.

|Jun 16, 2026
A distributed analysis approach for pharmacovigilance data from electronic medical records in German university hospitals: the POLAR_MI ETL Pipeline.

|Jun 12, 2026
Artificial intelligence-powered chatbots for oral anticancer drug patient information: an assessment of quality.

|Aug 28, 2025
Role of Transport Proteins for the Renal Handling of L-Arginine and Related Derivatives.

Lorenz A Scherpinski, Jörg König, Renke Maas

|Jun 24, 2025
Transport of the uremic toxin symmetric dimethylarginine (SDMA) by renal transport proteins.

Lorenz A Scherpinski, Martin F Fromm, Renke Maas

Pageof 3

Frequent Collaborators

10 joint publications

Martin F Fromm

7 joint publications

Wahram Andrikyan

4 joint publications

Pauline Dürr

3 joint publications

Arne Gessner